Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics develops treatments for serious immunological diseases, with company updates centered on atacicept, a self-administered fusion protein designed to block BAFF and APRIL activity involved in autoantibody production. News commonly covers the atacicept program in IgA nephropathy, related autoimmune kidney disease research, clinical data from the ORIGIN and PIONEER programs, FDA regulatory communications, and preparations tied to potential commercialization.
Other recurring developments include quarterly financial results, balance sheet and financing commentary, participation in health care conferences, board and executive appointments, and equity-based inducement awards under Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics (Nasdaq: VERA) reported that on July 6, 2026, its Board Compensation Committee granted inducement equity awards to eight new employees under the 2024 Inducement Plan. The grants include non-qualified stock options for 32,100 Class A shares at an exercise price of $40.13 and RSUs for 16,050 Class A shares, all vesting over four years, in accordance with Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics (Nasdaq: VERA) announced a planned transition of the Chief Regulatory Officer role. William Turner will retire and become Strategic Advisor in Q3 after helping secure accelerated approval of TRUTAKNA for IgA nephropathy. Nancy Boman, M.D., Ph.D., a veteran regulatory leader with experience at Kyverna, Adicet Bio, Encoded Therapeutics, Novartis Gene Therapies, Amgen, Genentech, and Alder, will succeed him as Chief Regulatory Officer, supporting new indications for TRUTAKNA and other pipeline programs.
Vera Therapeutics (Nasdaq: VERA) received FDA accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for progression. TRUTAKNA is a once-weekly 150 mg subcutaneous autoinjector that binds both BAFF and APRIL, targeting key immunological drivers of IgAN.
In the Phase 3 ORIGIN 3 interim analysis, TRUTAKNA achieved a 46% proteinuria reduction from baseline and 42% versus placebo at 36 weeks (p<0.0001), with generally well-tolerated safety. Continued approval may depend on confirming kidney function benefit, with eGFR results expected in Q3 2026.
Vera Therapeutics (Nasdaq: VERA) granted equity inducement awards on June 2, 2026 under its 2024 Inducement Plan, pursuant to Nasdaq Listing Rule 5635(c)(4).
The awards cover 28,800 stock options at a $31.26 exercise price and 14,150 RSUs for ten new employees, vesting over four years.
Vera Therapeutics (Nasdaq: VERA) announced U.S. FDA alignment on an earlier ORIGIN Phase 3 eGFR analysis for atacicept in adults with IgA nephropathy (IgAN).
The BLA for accelerated approval has a PDUFA date of July 7, 2026. eGFR results are expected in Q3 2026, supporting a planned sBLA in Q4 2026 and potential full approval in 2027.
Vera Therapeutics (Nasdaq: VERA) announced inducement awards granted May 4, 2026 to ten new employees under its 2024 Inducement Plan. The Compensation Committee granted non-qualified stock options for 40,250 shares and RSUs underlying 20,125 shares.
Each option has an exercise price of $35.51 (closing price May 4, 2026). Options vest over four years (25% after one year, then monthly over 36 months). RSUs vest 25% annually beginning May 20, 2026. Awards are subject to the Inducement Plan and individual award agreements.
Vera Therapeutics (NASDAQ: VERA) reported Q1 2026 results and a business update. The FDA granted Priority Review to the atacicept BLA for IgA nephropathy with a PDUFA date of July 7, 2026. The company expects a potential U.S. commercial launch in mid-2026, pending approval. Vera reported a Q1 net loss of $121.0 million and held $596.8 million in cash, equivalents and marketable securities as of March 31, 2026, which it says is sufficient to fund operations through potential approval and launch. Leadership promotions and hires were announced, and clinical readouts are expected in Q2 2026 and Q1 2027.
Vera Therapeutics (Nasdaq: VERA) will present at the Bank of America Securities 2026 Health Care Conference in Las Vegas from May 12–14, 2026. Management presentation is scheduled for May 13, 2026 at 4:20 PM PDT, and management will hold one-on-one investor meetings.
A live webcast is available at the provided URL and a replay will be accessible for 90 days via the company’s Investor Calendar. According to the company, the presentation is part of its investor outreach during the conference.
Vera Therapeutics (Nasdaq: VERA) announced inducement awards granted April 8, 2026 to 89 new employees under its 2024 Inducement Plan. The Compensation Committee approved non-qualified stock options for 258,200 shares and RSUs underlying 131,925 shares.
Options carry an exercise price of $40.33 per share (closing price on April 8, 2026) and vest over four years; RSUs vest annually over four years beginning May 20, 2026.
Vera Therapeutics (Nasdaq: VERA) announced inducement equity awards for its newly hired Chief Legal Officer, Jane Wright-Mitchell, approved March 23, 2026 under the 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The grants include non-qualified stock options to purchase 56,850 Class A shares at an exercise price of $40.73 (Vera's March 23 closing price) and restricted stock units underlying 42,403 Class A shares. Options vest over four years (25% at first anniversary, then monthly over 36 months). RSUs vest 25% on each anniversary beginning May 20, 2026. Awards are subject to the Inducement Plan and award agreements.